One in five (19%) firms over 200 workers covers GLP-1 agonists for weight loss with more coverage among larger firms One-in-five (19%) firms with 200 or more workers, including 43% of firms with 5,000 or more workers, cover GLP-1 drugs for weight loss in their largest health plan in 2025
Run, don't walk, from anyone trying to sell you these unproven compounds
Daily use of a broad-spectrum sunscreen with SPF 30 or higher is essential, even on cloudy days
Although the occurrence of different side-effects can lead to similar overall discontinuation rates, these findings raise the possibility that a large part of the treatment discontinuation is driven by patient-specific factors that affect treatment adherence across various types of drugs rather than drug-specific factors (including side-effects or oral vs subcutaneous administration)
The decision to restart semaglutide should be made in consultation with a healthcare provider, who will consider the nature of the gallbladder issue, the treatment undertaken (such as cholecystectomy), and the patients current health status
Tissue-selective regulation of protein homeostasis and unfolded protein response signalling in sporadic ALS
